Drugs Made In America Acquisition DMAA
NASDAQ DMAA
$10.75 +0.02 (+0.23%)
As of: Aug 21, 2026 · 2:31 PM EDT

Drugs Made In America Acquisition (DMAA) Free Cash Flow (2025)

Drugs Made In America Acquisition's (DMAA) quarterly Free Cash Flow came in at -$125180.0 in Q4 2025, down 123.11% on a QoQ basis from -$56108.0 in Q3 2025.

Drugs Made In America Acquisition (DMAA) Free Cash Flow (2025) Analysis & Trends

Drugs Made In America Acquisition (DMAA) has 1 years of Free Cash Flow data on file, last reported at -$125180.0 in Q4 2025.

  • Quarterly Free Cash Flow changed N/A year-over-year to -$125180.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$539187.0 (changed N/A YoY) and the FY2025 annual result came in at -$539187.0, down 213.0% from the prior year.
  • Free Cash Flow slipped to -$125180.0 in Q4 2025, from -$56108.0 in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$56108.0 in Q3 2025 to a low of -$251244.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Free Cash Flow (Qtr)
1 Oxley Bridge Acquisition 585.76 Mn 585.76 Mn - -162,173.00
2 Launch Two Acquisition 557.86 Mn 557.86 Mn - -109,362.00
3 Drugs Made In America Acquisition 507.00 Mn 507.00 Mn - -
4 Cantor Equity Partners IV 468.00 Mn 468.00 Mn - -
5 GP-Act III Acquisition 401.06 Mn 401.06 Mn - -
6 Aldel Financial 397.49 Mn 397.49 Mn - 2.14 Mn
7 Republic Digital Acquisition 389.25 Mn 388.51 Mn - -58,765.00
8 Gores Holdings X 385.06 Mn 384.87 Mn - -267,322.00
9 Agriculture & Natural Solutions Acquisition 377.29 Mn 377.04 Mn - -
10 Drugs Made In America Acquisition 215.82 Mn 215.82 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 -125,180.00
Dec 31, 2025 -125,180.00
Sep 30, 2025 -56,108.00
Sep 30, 2025 -56,108.00
Jun 30, 2025 -106,655.00
Jun 30, 2025 -106,655.00
Mar 31, 2025 -251,244.00
Mar 31, 2025 -251,244.00